Research areas
Systems Pathology and Cancer
Why do some patients respond to therapy and some don’t? There is a growing need to personalise therapeutic treatments because human diseases are somewhat unique to the individual patient. Diagnostic assays detecting specific features (biomarkers) of a disease provide a framework to classify diseases according to their underlying molecular defects. In turn, the patient-specific molecular profile guides the clinician’s choice for therapy. Cancer is a remarkably heterogeneous disease and the increasing complexity of molecular changes that occur during tumour evolution highlights the importance of identifying events that drive this process. In pregnancy, cells from the fetus invade maternal tissue and this process has many similarities to how cancer spreads. During pregnancy, fetal placental trophoblast cells invade the maternal uterine decidua without being rejected by the maternal immune system - the pregnancy paradox. The maternal decidua harbours multiple populations of maternal immune cells, all of which extensively interact with the fetal trophoblasts. Up to 40% of decidual cells are leukocytes, and accumulating evidence suggests that fetal immune tolerance is established locally at the placenta to counteract these maternal immune cells. The immune system also restrains the growth of many early cancer lesions by the process of immune surveillance, where lesions are detected and removed. However, cancers that develop further into clinical disease escape immune surveillance and it is increasingly appreciated that overcoming immune surveillance is a critical acquired attribute of tumourigenesis.
The Reynolds lab is interested in identifying those molecular changes which drive disease with particular emphasis on 1) factors that mediate tumour invasion and 2) factors that mediate placental invasion. We are employing biochemistry, molecular biology and cell biology approaches to investigate the nature and context of these factors and how they impact upon human health.
PhD supervision
- Jessie Woon
Selected publications
-
Open access
Transcription factor NFE2L1 decreases in glomerulonephropathies after podocyte damage
Elshani, M., Um, I. H., Leung, S., Reynolds, P. A., Chapman, A., Kudsy, M. & Harrison, D. J., 29 Aug 2023, In: Cells. 12, 17, 2165.Research output: Contribution to journal › Article › peer-review
-
Open access
YAP translocation precedes cytoskeletal rearrangement in podocyte stress response: a podometric investigation of diabetic nephropathy
Haley, K., Elshani, M., Um, I. H., Bell, C., Caie, P. D., Harrison, D. J. & Reynolds, P. A., 15 Jul 2021, In: Frontiers in Physiology. 12, 10 p., 625762.Research output: Contribution to journal › Article › peer-review
-
Open access
The mechanobiology of kidney podocytes in health and disease
Reynolds, P. A., Jun 2020, In: Clinical Science. 134, 11, p. 1245–1253 9 p.Research output: Contribution to journal › Review article › peer-review
-
Open access
Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031
Sarr, A., Bré, J., Um, I. H., Chan, T. H., Mullen, P., Harrison, D. J. & Reynolds, P. A., 21 May 2019, In: Scientific Reports. 9, 13 p., 7643.Research output: Contribution to journal › Article › peer-review
-
Open access
Glutaminase inhibition in renal cell carcinoma therapy
Raczka, A. M. & Reynolds, P. A., 14 May 2019, In: Cancer Drug Resistance. 2, 9 p.Research output: Contribution to journal › Review article › peer-review
-
Open access
Podocyte injury elicits loss and recovery of cellular forces
Haley, K., Kronenberg, N. M., Liehm, P., Elshani, M., Bell, C., Harrison, D. J., Gather, M. C. & Reynolds, P. A., 27 Jun 2018, In: Science Advances. 4, 6, 9 p., eaap8030.Research output: Contribution to journal › Article › peer-review
-
Open access
Crumbs 3b promotes tight junctions in an ezrin-dependent manner in mammalian cells
Tilston-Lunel, A. M., Haley, K., Schlecht, N., Wang, Y., Chatterton, A. L. D., Moleirinho, S. L., Watson, A., Hundal, H., Prystowsky, M., Gunn-Moore, F. J. & Reynolds, P. A., 7 Oct 2016, In: Journal of Molecular Cell Biology. 8, 5, p. 439-455Research output: Contribution to journal › Article › peer-review
-
Open access
Willing to be involved in cancer
Gunn-Moore, F. J., Tilston-Lunel, A. M. & Reynolds, P. A., 18 Jul 2016, In: Genes. 7, 7, 13 p., 37.Research output: Contribution to journal › Review article › peer-review
-
Open access
Fibroblasts in head neck squamous cell carcinoma associated with perineural invasion have high level nuclear Yes-Associated Protein (YAP) expression
Wang, Y., Gersten, A., Moleirinho, S., Gunn-Moore, F., Reynolds, P. A. & Prystowsky, M., Dec 2015, In: Academic Pathology. 2, 4, 5 p.Research output: Contribution to journal › Article › peer-review
-
Open access
Human tissue in systems medicine
Caie, P. D., Schuur, K., Oniscu, A., Mullen, P., Reynolds, P. A. & Harrison, D. J., Dec 2013, In: FEBS Journal. 280, 23, p. 5949–5956Research output: Contribution to journal › Review article › peer-review